The Journal of the American Dental Association
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Am Dent Assoc, Vol 132, No 11, 1512.
© 2001 American Dental Association

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

NEWS

NUCLEIC ACID TEST SYSTEMS TO SCREEN FOR HIV AND HEPATITIS C

The U.S. Food and Drug Administration has licensed the first nucleic acid test, or NAT, systems intended to screen plasma donors. NAT systems are expected to help ensure the safety of plasma-derived products by permitting earlier detection of human immunodeficiency virus, or HIV, and hepatitis C virus, or HCV, in donors.

Although effective procedures for virus inactivation are required in the manufacturing of all U.S.-licensed plasma derivatives, removal of potentially infectious donations through donor screening limits the amount of virus contamination that the manufacturing process must clear.

NAT is a newly developed technology that allows very small amounts of genetic material, such as DNA and RNA, to be detected by a process of massive copying of a gene fragment. The systems permits highly sensitive detection of RNA from HIV type 1 (the HIV variant that is responsible for the vast majority of acquired immunodeficiency cases in the United States) and HCV in test pools of 512 plasma samples obtained from multiple donors. The use of pooled samples makes use of the NAT system cost-effective.

If the test pool is positive for either HIV or HCV, the individual donation suspected of containing a virus can be identified and excluded from manufacturing use. Also, the donor can be notified and deferred.

Currently, blood and plasma donors are tested for antibodies to HCV and HIV, as well as HIV-1 antigens, which are the virus’s own proteins. There is a "window period," however, during which a donor can be infected, but still test negative during screening.

With the use of NAT systems, the "window period" for detection of HCV is reduced from 82 days to 25 days. For HIV-1, the average window period with antibody tests is 22 days. The use of antigen testing shrinks the window period to 16 days, and testing using the NAT systems reduces it to 12 days.

According to a press release from the FDA, in clinical trials, the NAT systems detected a number of HIV and HCV infections that would have been missed by previously licensed test methods, thus confirming the effectiveness of these systems.





This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS